Overview
- The company submitted an SEC registration for a New York listing, naming Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan as lead bookrunners, and it has not yet set the share count or price range.
- Medline reported first-half 2025 net sales of $13.53 billion and profit of $655 million, reflecting 9.7% year-over-year revenue growth.
- Bloomberg has reported a potential $5 billion raise and a valuation as high as $50 billion, which could make the deal the biggest U.S. IPO of 2025 if completed before Dec. 31.
- Medline has been majority-owned by private equity firms Blackstone, Carlyle and Hellman & Friedman since a roughly $34 billion transaction in 2021.
- U.S. IPO activity has strengthened this year, though a government shutdown caused short-term delays, according to Reuters.